Company profile: DNA Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical development as a privately held company.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to DNA Therapeutics
GenVec
HQ: United States
Website
- Description: Provider of differentiated, proprietary biopharmaceutical technologies for the creation of therapeutics and vaccines, developing and commercializing product candidates through collaborations with leading companies and organizations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenVec company profile →
EnPlusOne Biosciences
HQ: United States
Website
- Description: Provider of an ezRNA platform enabling incorporation of standard and non-standard nucleobases and their modifications, supporting installation of standard and phosphorothioated backbones, and integrating 2' modifications essential for siRNA therapeutics and novel variants. Offers 3' modifications including linkers and chain terminators for emerging RNA therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EnPlusOne Biosciences company profile →
SalioGen
HQ: United States
Website
- Description: Provider of non-viral Gene Coding technology enabling precise integration of large or multiple whole genes without double-strand breaks or guide RNA, and of programs including SGT-1001 for Stargardt disease, one-time genetic medicines for cystic fibrosis, CAR-T cell engineering for cancer and autoimmune diseases with tissue-specific integration, and therapies for inherited retinal diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SalioGen company profile →
Avidity Biosciences
HQ: United States
Website
- Description: Provider of oligonucleotide-based therapies leveraging an Antibody Oligonucleotide Conjugates (AOCs) platform that combines monoclonal antibodies with oligonucleotides to target genetic drivers of disease. Pipeline includes AOC 1001 for DM1 (Phase 3) to reduce DMPK mRNA, AOC 1020 for FSHD (Phase 1/2) to reduce DUX4 mRNA/protein, and AOC 1044 for DMD exon 44 skipping (Phase 1/2).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avidity Biosciences company profile →
Foghorn Therapeutics
HQ: United States
Website
- Description: Provider of targeted therapies leveraging its Gene Traffic Control platform to modulate the chromatin regulatory system, including FHD-286, an enzymatic BRG1/BRM inhibitor for AML and MDS; a selective BRM inhibitor and degrader for cancers with BRG1 mutations; and an ARID1B degrader for cancers with ARID1A mutations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Foghorn Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for DNA Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to DNA Therapeutics
2.2 - Growth funds investing in similar companies to DNA Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for DNA Therapeutics
4.2 - Public trading comparable groups for DNA Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →